Nitroprusside Sodium — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV (continuous infusion)	0.5-10 mcg/kg/min (start at 0.5-1 mcg/kg/min and titrate to effect)	Continuous IV infusion	Duration: As needed, usually short-term (minutes to hours) Notes: Use with invasive blood pressure monitoring. Titrate to desired effect. Avoid prolonged use due to cyanide toxicity.
Cat	IV (continuous infusion)	0.5-8 mcg/kg/min (start at 0.5-1 mcg/kg/min and titrate to effect)	Continuous IV infusion	Duration: As needed, usually short-term Notes: Use with invasive blood pressure monitoring. Cats may be more sensitive to cyanide toxicity.
Horse	IV (continuous infusion)	0.5-5 mcg/kg/min (titrate to effect)	Continuous IV infusion	Duration: As needed, usually short-term Notes: Use with invasive blood pressure monitoring. Monitor for cyanide toxicity with prolonged use.
Cattle	IV (continuous infusion)	0.5-5 mcg/kg/min (titrate to effect)	Continuous IV infusion	Duration: As needed, usually short-term Notes: Not commonly used; use with caution and monitoring.
Small Ruminants	IV (continuous infusion)	0.5-5 mcg/kg/min (titrate to effect)	Continuous IV infusion	Duration: As needed, usually short-term Notes: Not commonly used; use with caution and monitoring.
Rabbit	IV (continuous infusion)	0.5-5 mcg/kg/min (titrate to effect)	Continuous IV infusion	Duration: As needed, usually short-term Notes: Not commonly used; use with caution and monitoring.
Birds/Poultry	IV (continuous infusion)	0.5-5 mcg/kg/min (titrate to effect)	Continuous IV infusion	Duration: As needed, usually short-term Notes: Not commonly used; use with caution and monitoring.

Clinical Indications & Species Uses

General Indications

Emergency reduction of blood pressure
Controlled hypotension during anesthesia
Adjunct in acute heart failure to reduce preload and afterload

Dog (Canine)

Hypertensive crisis (e.g., pheochromocytoma, renal disease)
Controlled hypotension during surgery
Acute congestive heart failure (pulmonary edema) as an adjunct
Management of severe systemic hypertension unresponsive to other agents

Cat (Feline)

Hypertensive crisis (e.g., chronic kidney disease, hyperthyroidism)
Controlled hypotension during surgery
Acute heart failure with pulmonary edema

Horse (Equine)

Hypertensive crisis (rare)
Controlled hypotension during surgery (e.g., for orthopedic procedures)

Cattle (Bovine)

May be used in experimental settings for controlled hypotension

Rabbit & Small Mammals

May be used in research for controlled hypotension

Pharmacology & Mechanism of Action

Drug Class: Vasodilator | Pharmacological Group: Nitrovasodilator

Mechanism of Action: Nitroprusside sodium is a potent, direct-acting vasodilator that relaxes both arterial and venous smooth muscle. Its mechanism involves the release of nitric oxide (NO), which activates soluble guanylyl cyclase, increasing intracellular cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to dephosphorylation of myosin light chains and subsequent smooth muscle relaxation. This results in rapid reduction of peripheral vascular resistance (afterload) and venous return (preload), thereby decreasing myocardial oxygen demand and blood pressure.

Pharmacodynamics: Nitroprusside produces a rapid, titratable reduction in blood pressure. It dilates both resistance and capacitance vessels, leading to decreased systemic vascular resistance and central venous pressure. It also reduces pulmonary vascular resistance and may improve cardiac output in patients with heart failure. The onset of action is immediate (within 1-2 minutes) and the duration is very short (1-10 minutes) after discontinuation, making it ideal for emergency hypertensive crises and controlled hypotension during surgery.

⚡ Pharmacokinetics Summary

Absorption: Nitroprusside is administered intravenously; absorption is not applicable as it is given directly into the bloodstream.

Distribution: It distributes rapidly into the extracellular fluid. It does not cross the blood-brain barrier significantly. It crosses the placenta and may be distributed into milk.

Metabolism: Nitroprusside is metabolized rapidly in red blood cells and tissues. It reacts with sulfhydryl groups in erythrocytes to release cyanide, which is then converted to thiocyanate by the liver enzyme rhodanese (thiosulfate sulfurtransferase). Thiocyanate is excreted renally.

Excretion: Cyanide is converted to thiocyanate, which is excreted by the kidneys. The half-life of thiocyanate is about 3-4 days in normal renal function but can be prolonged in renal impairment.

Half-Life: Nitroprusside itself has a half-life of only a few minutes; thiocyanate has a half-life of 3-4 days (dogs, cats, humans).

Bioavailability: Not applicable (IV administration only).

Protein Binding: Nitroprusside is not significantly protein-bound; thiocyanate is minimally bound.

Available Formulations & Strengths

Injectable Solution 50 mg/5 mL (10 mg/mL) in 5 mL vials (IV)

Injectable Solution (diluted) Typically diluted in 5% dextrose in water to a concentration of 200 mcg/mL for infusion (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to nitroprusside
Severe hepatic insufficiency (impaired cyanide detoxification)
Severe renal insufficiency (impaired thiocyanate excretion)
Compensatory hypertension (e.g., arteriovenous shunt, coarctation of aorta)
Congenital optic atrophy or tobacco amblyopia (due to potential cyanide toxicity)
Use in patients with inadequate cerebral perfusion (e.g., increased intracranial pressure)

Warnings & Clinical Precautions:

Use with extreme caution in patients with hepatic or renal dysfunction.
Monitor blood pressure continuously with an arterial line.
Prolonged infusion (>24 hours) or high doses increase risk of cyanide toxicity.
Protect solution from light; wrap infusion bag and tubing in opaque material.
Do not mix with other drugs in the same IV line.
Use in pregnant animals only if clearly needed; may cause fetal cyanide toxicity.
Discontinue gradually to avoid rebound hypertension.
Monitor for metabolic acidosis, which may indicate cyanide toxicity.

Adverse Effects & Reactions

Common:

Hypotension
Tachycardia
Nausea and vomiting (in humans; may occur in animals)
Headache (in humans; may occur in animals)
Diaphoresis

Serious / Severe:

Cyanide toxicity (with prolonged use or high doses)
Thiocyanate toxicity (with renal impairment)
Metabolic acidosis
Severe hypotension leading to shock
Myocardial ischemia
Cerebral ischemia

Rare:

Methemoglobinemia
Hypothyroidism (with prolonged thiocyanate exposure)
Allergic reactions

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Other antihypertensive agents (e.g., ACE inhibitors, beta-blockers)	Additive hypotensive effect; may require dose reduction.	Moderate
Inhalational anesthetics (e.g., isoflurane, sevoflurane)	Additive hypotension; may enhance hypotensive effect.	Moderate
Sildenafil and other PDE5 inhibitors	Severe hypotension due to additive vasodilation.	High
Sodium thiosulfate	May be used concurrently to reduce cyanide toxicity; thiosulfate enhances conversion of cyanide to thiocyanate.	Mild (beneficial)
Vitamin B12 (hydroxocobalamin)	May be used to treat cyanide toxicity; can bind cyanide.	Mild (beneficial)

Overdose & Toxicity Management

Signs of Toxicity:

Severe hypotension
Tachycardia
Metabolic acidosis
Cyanide toxicity signs: dyspnea, seizures, coma, cardiac arrhythmias
Thiocyanate toxicity signs: confusion, weakness, hyperreflexia, seizures

Emergency Treatment Protocol: Discontinue infusion immediately. Provide supportive care: administer IV fluids, vasopressors (e.g., norepinephrine) if needed. For cyanide toxicity, administer sodium thiosulfate (150-200 mg/kg IV) and/or hydroxocobalamin (70 mg/kg IV in dogs; dose for other species may vary). For thiocyanate toxicity, consider hemodialysis if severe. Monitor blood gases, lactate, and cyanide levels if available.

Food Animal Withdrawal Times

Not approved for food animals; use is extra-label. Withdrawal times not established. If used in food animals, consult FARAD (Food Animal Residue Avoidance Databank) for guidance.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C; excursions permitted to 15-30°C).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Store in original carton. Diluted solutions should be used within 24 hours and protected from light.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not specifically approved for veterinary species, but used extra-label in veterinary medicine.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is permitted under AMDUCA with veterinary oversight, but withdrawal times must be extended and FARAD consulted. In non-food animals, use is generally accepted.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Nitroprusside sodium is a potent, short-acting vasodilator used in veterinary medicine primarily for hypertensive emergencies and controlled hypotension during anesthesia. It requires continuous IV infusion and invasive blood pressure monitoring. Due to the risk of cyanide toxicity, its use should be limited to short durations (preferably <24 hours) and at the lowest effective dose. It is particularly useful in cases of acute heart failure with pulmonary edema, where it reduces both preload and afterload. However, it should be used with caution in animals with hepatic or renal impairment. Alternative agents such as hydralazine or amlodipine may be considered for longer-term management of hypertension. Always have sodium thiosulfate or hydroxocobalamin available when using nitroprusside.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)